être Venture Capital

être Venture Capital is a venture capital firm based in Santa Cruz, California, founded in 2022. The firm is led by women and focuses on supporting mission-driven entrepreneurs. It specializes in pre-seed and series investments in startup companies, providing both financial backing and advisory services to help these businesses grow and succeed. By emphasizing a commitment to purpose-driven ventures, être Venture Capital aims to foster innovation and sustainability in the entrepreneurial landscape.

Jennifer Kuan

Managing Partner

Hillary Talbot

Managing Partner

3 past transactions

Hexas Biomass

Venture Round in 2022
Hexas Biomass specializes in producing sustainable non-wood biomass that serves as a substitute for traditional wood and fossil fuel-based raw materials. The company utilizes a high-yielding perennial biomass crop that grows in diverse climates and requires minimal inputs, ensuring it does not compete with food crops. This innovative fiber can be employed across various industries, enabling the creation of forestry-free products such as fiberboard, sustainable packaging, and biofuels. By providing eco-friendly alternatives, Hexas Biomass supports clients in their efforts to replace conventional wood and petroleum-based materials with more sustainable options.

Portico Wellness

Venture Round in 2022
Portico Wellness is a mental health platform designed to facilitate access to mental health care services for employees and employers. The platform enables users to find, connect with, and schedule appointments with independent psychologists, social workers, therapists, and other related service providers. By removing barriers to the mental health care process, Portico Wellness enhances the experience for individuals seeking support while also integrating with employee compensation benefits. This streamlined approach aims to improve access to essential mental health resources in the workplace.

Obatala Sciences

Series A in 2022
Obatala Sciences is a biotechnology company focused on addressing the economic challenges posed by obesity and diabetes, which collectively amount to a substantial financial burden. The company has developed a humanized adipose tissue model system that serves as an advanced in vitro platform for tissue engineering and drug discovery. This three-dimensional screening tool facilitates disease modeling, cell assays, and tissue analysis, thereby enabling academic and pharmaceutical researchers to identify effective drug compounds more efficiently. By emphasizing the role of body fat as a functional organ that regulates health and disease, Obatala Sciences aims to streamline the testing processes for potential treatments targeting obesity, diabetes, and related metabolic diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.